





## Optimizing Outcomes in the Management of CLL: The Evolving Role of the Clinical Pharmacist



Panel

**John Allan, MD**

Hematology Oncology



**Victoria Nachar, PharmD, BCOP**

Hematology Clinical Pharmacist Specialist  
University of Michigan Rogel Cancer Center

### Background

With the increasing use of oral oncolytics, the treatment landscape has evolved in chronic lymphocytic leukemia (CLL). Dr. Allan and Dr. Nachar shared their perspectives on the expanding role of the clinical pharmacist in the CLL treatment setting.

### Key Highlights

- 1 Clinical pharmacists are assuming greater responsibilities in the treatment of patients with CLL, including safety monitoring, adherence support, and involvement in shared decision-making
- 2 Patient education and financial assistance support remain important functions of the clinical pharmacist and the clinical pharmacy team
- 3 Engagement with the multidisciplinary care team and clinician support may lead to better outcomes and increased efficiencies

"I think the role of the pharmacist within the multidisciplinary team has evolved, and I think in all steps of the process, there is room for pharmacists' involvement to **ultimately improve the quality of care** that patients receive."

— Dr. Victoria Nachar

## Role of the Clinical Pharmacist in CLL



Patient education and ongoing follow-up



Shared decision-making



Patient safety monitoring, including drug-drug interactions and comorbid conditions



Financial assistance support (eg, navigating prior authorizations and identifying co-pay foundation support)



Adherence support



Clinician support

"I think it's an invaluable relationship that we have with our pharmacists in terms of education, compliance, safety. And I think **these all ultimately relay down to improved health and less healthcare utilization...**"

— Dr. John Allan

## Additional Resources

Chen KY, Brunk KM, Patel BA, et al. Pharmacists' role in managing patients with chronic lymphocytic leukemia. *Pharmacy (Basel)*. 2020;8(2):52.

Hematology/Oncology Pharmacy Association (HOPA). *Further Defining the Scope of Hematology/Oncology Pharmacy Practice*. HOPA; 2019. Accessed August 8, 2023. [https://www.hoparx.org/documents/94/HOPA18\\_Scope-2\\_Web2.pdf](https://www.hoparx.org/documents/94/HOPA18_Scope-2_Web2.pdf)

Holle LM, Segal EM, Jeffers KD. The expanding role of the oncology pharmacist. *Pharmacy (Basel)*. 2020;8(3):130.

Ignoffo RJ, Knapp KK, Seung A, et al. Trends in the delivery of care to oncology patients in the United States: emphasis on the role pharmacists on the healthcare team. *J Oncol Pharm Practice*. 2021;27(1):5-13.

Visit **BeOneEngage.com** for additional information and resources.



Scan with your smartphone camera to visit the site



BeOne Medicines trademark is owned by BeOne Medicines USA Inc. or its affiliates.  
© BeiGene, Ltd. 2025 All Rights Reserved.  
0823-NP-PRC-011 Date of preparation: March 2025